Shinobi Therapeutics, a trailblazer in immune evasive iPS cell therapies, has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). This significant grant will accelerate the development of Shinobi’s pioneering iPS-T cell therapy, aimed at treating GPC3+ solid tumors.
Dr. Yasumichi Hitoshi, Chief of Staff and Shinobi Japan’s Representative Director, expressed enthusiasm for the support from AMED, highlighting it as a crucial endorsement of their innovative technology. The grant underscores Shinobi’s commitment to advancing cancer treatments through cutting-edge research.
In addition to this grant, Shinobi has expanded its Series A funding round, bringing the company’s total funding to $119 million. The latest investments from Yosemite and Mitsubishi UFJ Capital reflect growing confidence in Shinobi’s technology, which leverages a decade of research by co-founders Dr. Tobias Deuse and Dr. Shin Kaneko. Their immune evasive iPS-T cell platform promises to revolutionize cell therapy by providing off-the-shelf solutions that align with patients’ immune systems.
Dan Kemp, CEO of Shinobi Therapeutics, commended the AMED grant as a powerful endorsement of their efforts and a catalyst for accelerating their oncology program. This grant, coupled with strategic partnerships with Panasonic for manufacturing and Anocca for TCR discovery, positions Shinobi at the forefront of cell therapy innovation.
Editorial Perspective: Shinobi Therapeutics’ recent achievements underscore the transformative potential of iPS cell technology in oncology. The substantial AMED grant not only highlights the company’s groundbreaking work but also aligns with global trends toward advanced, accessible cancer treatments. As Shinobi continues to advance its iPS-T cell therapies, it stands poised to make a significant impact on the treatment landscape, bridging cutting-edge science with real-world applications.
The company’s expansion and partnerships further reflect a robust strategy for scaling their innovations and addressing unmet needs in cancer care. With continued support and strategic development, Shinobi Therapeutics is well-positioned to drive substantial advancements in the field of immuno-oncology.
For additional details or inquiries, please contact editor@thetimesmag.com.
